Viasat Confirms Successful Launch of ViaSat-3 F2 Cofttek, China’s Largest Manufacturer of PEA, Draws Attention of Investors
LUOHE CITY, China, Feb 14, 2021 – (ACN Newswire) – Cofttek Holding Limited, a Chinese…
Yutong Bus to serve FIFA Club World Cup Qatar 2020
ZHENGZHOU, China, Feb 14, 2021 – (ACN Newswire) – On 4 February 2021, the 17th…
Longhua District Carries out Future City Scenes Experiment
SHENZHEN, CHINA, Feb 13, 2021 – (ACN Newswire) – On the morning of February 4,…
3 Tips From Wealth Management Advisor, Andrew Rogel, To Help You Take Your Finances to the Next Level
LA JOLLA, CA / ACCESSWIRE / February 12, 2021 / WestPac Wealth Partners started 13…
How Buyers Can Navigate The New Home Construction Process From Start to Finish, Top Tips from Real Estate Agent Christina Zamora
SHERMAN OAKS, CA / ACCESSWIRE / February 12, 2021 / Colorado native, Christina Zamora, has…
American IRA Explains How to Get Started with Real Estate Investing Through a Self-Directed IRA
ASHEVILLE, NC / ACCESSWIRE / February 13, 2021 / How do investors get started with…
Local Company Offering Commercial Cleaning Sydney Explains COVID Precautions and its Consistently Highly Rated Performance
SYDNEY, AUSTRALIA / ACCESSWIRE / February 12, 2021 / The people who run Clean Group…
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a…
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
COSELA (trilaciclib) image COSELA (trilaciclib) image – COSELA is the only FDA-approved therapy that helps…
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or…
Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs
LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical…
Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $34.3 Million
LAKE FOREST, Ill., Feb. 12, 2021 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the…
Cassava Sciences Announces Closing of $200 Million Registered Direct Offering
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”…
Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc…
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use…
Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium (ETH), Bitcoin Cash (BCH), Dai (DAI), and Litecoin (LTC)
Tauriga Sciences, Inc. Tauri-Gum Store: E-Commerce Checkout Page The Acceptance of Bitcoin, and These Other…
Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line
NEW YORK, NY , Feb. 12, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc….
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results…
Radius Health, Inc. Provides Abaloparatide Business Update
17% growth in January 2021 for new TYMLOS® patients vs. previous 4 month trailing average…
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV)…